At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Su Pin Choo, MBBS, MRCP(UK), FAMS, from the National Cancer Centre Singapore, Singapore, discusses the development of immunotherapy for patients with hepatocellular carcinoma (HCC), including early promising clinical data with nivolumab, a programmed cell death-1 (PD-1) antibody.
Immunotherapy for hepatocellular carcinoma
25 May 2016
Oncology
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.